Vis enkel innførsel

dc.contributor.advisorHalvorsen, Kjell H
dc.contributor.authorHavnes, Kjerstin
dc.date.accessioned2022-11-21T10:12:31Z
dc.date.available2022-11-21T10:12:31Z
dc.date.issued2022-12-14
dc.description.abstract<p><i>Background -</i> Drug therapy contributes to healthy aging but has a key duality: It prolongs and can improve quality of life, but drugs can also cause serious harm. Harm from drugs include falls, cognitive decline, lowered quality of life, hospitalisation, and death. Older patients are especially at risk for harm from drug therapy, therefore optimising drug therapy is imperative for this group. <p><i>Aim -</i> To generate new knowledge of drug therapy optimisation for older patients by exploring the impact of drug burden and investigating different approaches to optimise drug therapy across the patient pathway. <p><i>Methods -</i> This thesis used data from The Norwegian patient registry, The Norwegian Prescription Database and data collected in a randomised controlled trial (RCT). Observational data of the delivery of the RCT-intervention was included. In Paper I the association between anticholinergic (AC) and sedative (SED) drug burden and post-discharge institutionalisation (PDI) was assessed using multiple regression. Paper II described an RCT investigating the effect of an in-hospital pharmacist intervention. Paper III presented the fidelity and process outcomes of the intervention (Paper II). In Paper IV, an observational tool was developed and time distribution for the pharmacists running the RCT examined. <p><i>Results -</i> Number of drugs used before hospitalisation was mean 7.11 (SD 4.09) and at hospitalisation median 6.0 (range 4-9). Prevalence of AC/SED drugs was 45.5%. All measures of AC/SED drug burden was significantly associated with PDI. The number of AC drugs were most sensitive (OR 1.13, per AC drug), and the DBI most challenging to apply. The clinical pharmacist contributed to identify and solve discrepancies for 72% of the patients (median 1) and DRPs for 94.6% of the patients (median 4), and the acceptance rate was 67%. Intervention fidelity at admission was 100%, and 57% overall. The pharmacists advanced communication of drug therapy across the patient pathway. About 41% of pharmacist time was spent on administrative RCT-tasks and the estimated intervention time was >3.5 hours/patient. <p><i>Conclusions -</i> The drug burden is high in older patients acutely admitted to hospital in Norway and assessing AC/SED drug use can reduce the risk of PDI. The in-hospital pharmacist intervention contributed to drug therapy optimisation and facilitated communication across the patient pathway. These measures can contribute to optimisation of drug therapy but are time consuming and costly. It is essential to establish models for drug therapy optimisation across the pathway, including primary care.en_US
dc.description.doctoraltypeph.d.en_US
dc.description.popularabstractBackground The number of old people is expected to increase worldwide. From 2015 to 2050, the number of people >60 is predicted to more than double. By 2050, a third of the European population will be 60+ years. Hence, it will be essential to maintain old people’s functional ability, to enable well-being in older age. One key factor in this picture is drug therapy. However, drug therapy has two sides. On one hand, drug therapy prolongs life span and reduces loss of life, it relieves symptoms and increases the quality of life. On the other hand, drug therapy can cause serious harm and be a burden for patients. Harm from drugs can include falls, cognitive decline, lowered quality of life, hospitalisation, and death. Old people are particularly vulnerable to and often experience harmful effects of drug therapy. Some drug classes, such as anticholinergic (AC) and sedative (SED) drugs, are considered high-risk for older patients. They affect the patient’s nervous system, which can increase the risk of falling, make the patients confused, or even delirious. When drug therapy potentially and/or cause harm, or hinder the wanted result from treatment, that is known as “drug related problems”. To enable healthy ageing, optimising drug therapy may have an influence. Optimising drug therapy is both to ensure the quality of the patient’s drug therapy, and to make certain that sufficient information about the drug therapy is provided to patients, careers, and through transitions to and from hospital. This thesis addresses drug therapy optimisation for older patients in Norwegian health care. It focuses on measures to improve drug therapy for older patients. Many approaches to optimise drug therapy exist. One is to use defined tools to identify drug related problems, for example by evaluating specific drug classes known to be at risk for older patients, another is to use the competency of pharmacists, who have drug therapy as their specialty. Aim The aim of this thesis is to find new knowledge of drug therapy optimisation for older patients by exploring the impact of drug burden and to investigate different approaches to optimise drug therapy for older patients. Method This thesis used different sources of data. Data from two Norwegian health registries provided information on i) old patients hospital stays (from The Norwegian patient registry) and, ii) old patients drug therapy based on dispensed prescriptions from pharmacies (from The Norwegian Prescription Database). We also collected data in a clinical trial where we investigated the effect of having pharmacist in the teams responsible for the patient’s drug therapy in-hospital. Together, these data shed light on the patient’s drug therapy and drug burden connected to hospitalisations. In addition, the pharmacists were observed, to see how they spent their time when working in the trial. Four papers are included in this work. In Paper I we investigated if and to what degree using anticholinergic (AC) and sedative (SED) drugs, affected where the hospitalised patients were discharged to; to an institution or home. In Paper II we described the trial and the planned intervention, how the pharmacist should work. Paper III present if the pharmacists managed to work according to the planned intervention, and the results from the intervention from Paper II. In Paper IV, we developed an observational tool to be able to measure the time distribution for the pharmacists in Paper II+III and observed the pharmacist in the trial. Results Older patient used an average of about 7 drugs before admission to hospital, and around 6 drugs on a regular basis at admission. Almost half of the patients investigated in Paper I used one or more AC/SED drugs (45.5%). The use of AC/SED drugs increased the risk of being discharged to an institution, use of AC drugs had the highest risk. On the other hand, the pharmacist in the clinical trial contributed to provide correct medication lists for the patients (72 % of the patients had errors in their lists), and to identify and solve drug related problems for the patients. Almost all patients (94%) had one or more problems related to their drug therapy, most of the patient had 4 drug related problems identified. The physicians in charge accepted almost seven of ten suggestions from the pharmacists to solve these problems. All patients in the trial (Paper II and III) received pharmacist services to provide correct lists of drug therapy (Medication reconciliation) and to identify drug related problems (Medication review). Almost six of ten patients received all steps of the intervention from the pharmacists (57%). The intervention steps at discharge, such as counselling of patients and phone calls to the general practitioner, were more challenging for the pharmacists to deliver. Still, the pharmacists ensured that information regarding the patients’ drug therapy followed the patients across health care. When observing the pharmacists, we found that 41 % of the pharmacist time was spent on administrative work in the trial, not related to patients drug therapy. However, during the time they were observed, the pharmacists used more than 3.5 hours per patient to deliver the intervention. Conclusion Older patients with unplanned hospital stays in Norway use many drugs, and the drug burden is high. For older patients, one way to reduce the risk of being transferred to an institution from hospital is to reduce the use of AC drugs. We showed that pharmacists working in hospital teams helped to increased quality of drug treatment by identifying errors and solving them together with the hospital team. They also ensured that information regarding the patients’ drug therapy followed the patients across health care. These measures can contribute to optimisation of drug therapy for older patients, but they are time consuming and costly. It is essential to establish models for drug therapy optimisation across the patient pathway, including primary care.en_US
dc.identifier.urihttps://hdl.handle.net/10037/27431
dc.language.isoengen_US
dc.publisherUiT The Arctic University of Norwayen_US
dc.publisherUiT Norges arktiske universiteten_US
dc.relation.haspart<p>Paper I: Havnes, K., Svendsen, K., Johansen, J.S., Granas, A.G., Garcia, B.H. & Halvorsen, K.H. Is anticholinergic and sedative drug burden associated with post-discharge institutionalization in community-dwelling patients acutely admitted to hospital? A Norwegian registry-based study. (Submitted manuscript). <p>Paper II: Johansen, J.S., Havnes, K., Halvorsen, K.H., Haustreis, S-M., Skaue, L.W., Kamycheva, E., ... Garcia, B.H. (2018). Interdisciplinary collaboration across secondary and primary care to improve medication safety in the elderly (IMMENSE study): study protocol for a randomised controlled trial. <i>BMJ Open, 8</i>(1), e020106. Also available in Munin at <a href=https://hdl.handle.net/10037/12569>https://hdl.handle.net/10037/12569</a>. <p>Paper III: Johansen, J.S., Halvorsen, K.H., Havnes, K., Wetting, H.L., Svendsen, K. & Garcia, B.H. (2021). Intervention fidelity and process outcomes of the IMMENSE study, a pharmacist-led interdisciplinary intervention to improve medication safety in older hospitalized patients. <i>Journal of Clinical Pharmacy and Therapeutics, 47</i>(5), 619-627. Also available in Munin at <a href=https://hdl.handle.net/10037/23991>https://hdl.handle.net/10037/23991</a>. <p>Paper IV: Havnes, K., Lehnbom, E.C., Walter, S.R., Garcia, B.H. & Halvorsen, K.H. (2021). Time distribution for pharmacists conducting a randomized controlled trial — An observational time and motion study. <i>PLoS ONE, 16</i>(4), e0250898. Also available in Munin at <a href=https://hdl.handle.net/10037/21644>https://hdl.handle.net/10037/21644</a>.en_US
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2022 The Author(s)
dc.subject.courseIDDOKTOR-003
dc.subjectOlder patientsen_US
dc.subjectHospitalisationen_US
dc.subjectAnticholinergicsen_US
dc.subjectSedativesen_US
dc.subjectClinical pharmacyen_US
dc.subjectDrug Burden Indexen_US
dc.subjectInstitutionalisationen_US
dc.subjectHealth registriesen_US
dc.subjectDrug therapyen_US
dc.subjectGeriatricen_US
dc.subjectRandomised controlled trialen_US
dc.subjectDrug related problemsen_US
dc.subjectWOMBATen_US
dc.subjectPatient pathwayen_US
dc.titleOptimising drug therapy in older patients. Exploring different approaches across the patient pathwayen_US
dc.typeDoctoral thesisen_US
dc.typeDoktorgradsavhandlingen_US


Tilhørende fil(er)

Thumbnail
Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel